Skip to content
ClinCalc Pro
Menu
IBAT (apical sodium-bile acid transporter) inhibitor

Odevixibat

Brand names: Bylvay

Odevixibat is an ileal bile acid transporter inhibitor used to treat cholestatic pruritus in progressive familial intrahepatic cholestasis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively inhibits the ileal bile acid transporter, reducing reabsorption of bile acids from the terminal ileum and thereby lowering circulating bile acid levels that contribute to pruritus.

Prescribing in practice

  • Diarrhoea and disturbances in liver biochemistry are recognised effects, so liver function and fat-soluble vitamin status should be assessed during treatment.
  • It is given orally and, in young children, can be administered with food as set out in the prescribing information.
  • Interrupt or adjust treatment if there is a significant rise in liver enzymes or persistent diarrhoea.

Monitoring

Monitor liver function tests, serum bile acids and fat-soluble vitamin levels, and review growth and hydration in children.

Counselling the patient

  • Advise families that loose stools can occur and to report persistent diarrhoea or signs of dehydration.
  • Explain that the medicine aims to relieve itching and that regular blood tests are needed.

Evidence & guidelines

Odevixibat is used for cholestatic pruritus in progressive familial intrahepatic cholestasis in line with its licensed indication and specialist hepatology practice.

Reference: NICE; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.